Bortezomib (PS-341)
Katalog-Nummer M1686-50mg
Size : 50mg
Marke : AbMole Bioscience
All AbMole products are for research use only, cannot be used for human consumption.
Velcade; PS-341; LDP 341; MG 341; NSC 681239
Quality Control & Documentation
Biological Activity
Bortezomib (PS-341) is a highly selective, reversible inhibitor of the 26S proteasome with a ki value of 6nM, which has shown high antimyeloma activity. Bortezomib caused comparable growth suppression in LNCaP-Pro5 and PC3M-Pro4 cells with an IC90 of 10 nM.
Product Citations
-
Cancer Lett. 2024 Apr 6;590:216861.
TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma
Bortezomib (PS-341) purchased from AbMole -
Mol Ther Oncol. 2024 Apr 11;32(2):200802.
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation
Bortezomib (PS-341) purchased from AbMole -
Cell Death Differ. 2023 Mar 9.
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα
Bortezomib (PS-341) purchased from AbMole -
BMC Biol. 2023 Apr 7;21(1):75.
1, 6-Hexanediol regulates angiogenesis via suppression of cyclin A1-mediated endothelial function
Bortezomib (PS-341) purchased from AbMole -
Sci Rep. 2020 Feb 25;10(1):3386.
Gender-specific Changes in Energy Metabolism and Protein Degradation as Major Pathways Affected in Livers of Mice Treated With Ibuprofen
Bortezomib (PS-341) purchased from AbMole -
Cell Physiol Biochem. 2018;50(6):2341-2364.
Peperomin E Induces Promoter Hypomethylation of Metastatic-Suppressor Genes and Attenuates Metastasis in Poorly Differentiated Gastric Cancer.
Bortezomib (PS-341) purchased from AbMole -
Int J Oncol. 2016 Oct;49(4):1469-78.
Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis
Bortezomib (PS-341) purchased from AbMole
Customer Product Validations & Biological Datas
Source | INTERNATIONAL JOURNAL OF ONCOLOGY (2016) . Figure 9. Bortezomib (M1686) was from Abmole Bioscience Inc. (Houston, TX, USA) | |
Method | FACS | |
Cell Lines | B cells from CD19 cre/+Foxo1F/+ and CD19 cre/+Foxo1F/F mice | |
Concentrations | 0.05 μg/ml | |
Incubation Time | 24 h | |
Results | The effect of Foxo1-defciency on cell apoptosis was approved by using B cells from CD19cre/+Foxo1F/+ and CD19cre/+Foxo1F/F (Fig. 9D). |
Source | INTERNATIONAL JOURNAL OF ONCOLOGY (2016) . Figure 5. MBortezomib (M1686) was from Abmole Bioscience Inc. (Houston, TX, USA) | |
Method | FACS | |
Cell Lines | SP2/0 cells | |
Concentrations | 0, 0.05 and 0.25 μg/ml | |
Incubation Time | 24 h | |
Results | Low dose of bortezomib, frst-line drug in patients with newly diagnosed multiple myeloma, could effectively induce apoptosis and Grm3 expression (Fig. 5). |
Protocol (for reference only)
Cell Experiment | |
---|---|
Cell lines | Nine canine melanoma cell lines (CMM-1, CMM-2, ChMC, KMeC, LMeC, OMJ, OMS, OMK, and NML) |
Preparation method | Cell growth inhibition assay Nine canine melanoma cell lines (CMM-1, CMM-2, ChMC, KMeC, LMeC, OMJ, OMS, OMK, and NML) were cultured in 96-well plates (2 *102 cells/well) for 24 h in cDMEM and treated with different concentrations of bortezomib (0–100 nM) for 72 h. Cell viability was then measured by a WST-1 cell proliferation assay kit (Takara) and the half maximal inhibitory concentration (IC50) of bortezomib for each cell line was calculated using the GraphPad Prism software (GraphPad Software). |
Concentrations | 0–100 nM |
Incubation time | 72 h |
Animal Experiment | |
---|---|
Animal models | CMM-1 cells in xenograft mouse models |
Formulation | 100 µL PBS containing 4.2% DMSO |
Dosages | 0.8mg/kg twice weekly |
Administration | intravenous(IV) injections |
Chemical Information
Molecular Weight | 384.24 |
Formula | C19H25BN4O4 |
CAS Number | 179324-69-7 |
Solubility (25°C) | DMSO 72 mg/mL |
Storage | 2-8°C, protect from light |
References
[1] Andrew Sandstrom, et al. Science. Functional degradation: A mechanism of NLRP1 inflammasome activation by diverse pathogen enzymes
[2] Ashley J Chui, et al. Science. N-terminal degradation activates the NLRP1B inflammasome
[3] Koda et al. Rinsho Ketsueki. Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients.
[4] Rushworth et al. Cell Signal. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
[5] Chauhan et al. Cancer Cell. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
[6] Jung et al. Am J Hematol. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.